RasCase – sayretherapeutics

RasCase®

Rasburicase Injection (r-DNA origin) 1.5mg

Sayre Therapeutics offers clinicians an FDA approved option to manage Tumor Lysis Syndrome.

Indication

FDA approved for the prevention and treatment of Tumor Lysis Syndrome (TLS).

Formulation

Rasburicase Injection 1.5 mg for Intra venous administration.

RasCase®is

An offering for haematologists and medical oncologists to manage TLS.
Backed by robust evidence from International trials and an Indian Phase III trial with 100 patients published in Indian Journal of Cancer.

What is TLS ?

A condition in which tumour cells release their content into bloodstream either spontaneously or in response to chemotherapy.
Most common in rapidly growing haematologic malignancies but has been reported in virtually every cancer type.
Prevention is the key as management can be challenging.

Quick Link

Get in Touch

Mail ID:

info@sayretherapeutics.com

Landline:

+91 8048666604

Mobile: +91 9591736262

WhatsApp: +91 9591736262

Copyright ©2025. All Rights Reserved